An interventional study of Paclitaxel Drug-coated balloon in Coronary Artery Disease and Total Occlusion of Coronary Artery, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by National Institute of Cardiology, Warsaw, Poland · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · National Institute of Cardiology, Warsaw, Poland.
Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, this one is the 12th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 15th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland are open now, in 1 country. Recruiting first, the newest first:
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18+
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18–80
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18+
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18–75
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 97 across the 12 interventional studies, 336 across the 6 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Cardiology, Warsaw, Poland is the lead sponsor of 54 studies on the registry; 12 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The IMAGINATION trial is an investigator-initiated, prospective, single-center study of symptomatic patients with a native chronic total occlusion (CTO) undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) with a drug-coated balloon (DCB). Post-PCI IVUS and fractional flow reserve (FFR) at baseline and at 6-months follow-up will be performed. In addition, patients included in the coronary computed tomography angiography (CCTA) substudy will undergo CCTA at 12-months follow-up. The aim of this study is to evaluate the efficacy and safety of DCB-only approach in native coronary CTO.
Whereas CTO PCI techniques and success rates have significantly improved during the last decade, CTOs still pose a significant technical challenge for accurate stent sizing (primarily due to negative remodelling and subsequent distal vessel dilatation post-PCI) resulting in a potentially increased risk of stent failure. Hence, the concept of DCB as a definitive treatment for native CTO is appealing and warrants further investigation. The IMAGINATION trial has been designed as a prospective research to: 1) investigate both the immediate and intermediate-term angiographic, IVUS and physiologic efficacy outcomes as well as safety profile of DCB for native vessel coronary CTO, and 2) to provide a basis for future randomized clinical trial comparing DCB to drug-eluting stents.
All patients with CTO will be screened for potential inclusion in the study. After obtaining written informed consent, patients with successful intraplaque guidewire crossing through CTO lesion (excluding the use of dissection and re-entry techniques) will undergo IVUS-guided PCI with a scoring balloon (balloon-to-artery ratio of 1:1) followed by the use of a paclitaxel-coated balloon. Following satisfactory angiographic result, IVUS and physiological measurements (FFR and non-hyperemic pressure ratios) in the target vessel will be performed. At 6-months follow-up, invasive angiography with IVUS and FFR/non-hyperemic pressure ratios in the target vessel will be repeated. In addition, patients with pre-procedural CCTA will undergo follow-up CCTA after 12 months (CCTA substudy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo PCI of the native coronary CTO with a DCB.
Device: Paclitaxel Drug-coated balloon
Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
In-segment late lumen loss
The difference by subtracting the minimal lumen diameter (MLD) at follow-up from the MLD postprocedure. In-segment equals DCB plus the proximal and distal 5-mm margins.
Time frame: 6-months
Angiographic outcomes assessed directly post-PCI
* minimum lumen diameter (mm) * residual diameter stenosis (%) * the rate of bail-out stenting after DCB use (%)
Time frame: immediately post-procedure (1 day)
HD-IVUS outcomes assessed directly post-PCI
* minimal lumen diameter (mm) * minimal lumen area (mm2) * maximum plaque burden (%)
Time frame: immediately post-procedure (1 day)
Physiologic outcomes assessed directly post-PCI
* the ratio of pd/pa * cRR (absolute values) * FFR (absolute values)
Time frame: immediately post-procedure (1 day)
Angiographic outcomes at 6-months follow-up
* minimum lumen diameter (mm) * residual diameter stenosis (%) * in-segment binary restenosis (≥50% diameter stenosis) * the rate of target vessel re-occlusion (yes/no)
Time frame: 6-months
HD-IVUS outcomes at 6-months follow-up
* minimal lumen diameter (mm) * minimal lumen area (mm2) * maximum plaque burden (%)
Time frame: 6-months
Physiologic outcomes at 6-months follow-up
* the ratio of pd/pa * cRR (absolute values) * FFR (absolute values)
Time frame: 6-months
Computed tomographic outcomes at 12-months follow-up (CCTA substudy)
* minimal lumen area (mm2) * maximum plaque burden (%) * area stenosis (%) * diameter stenosis (%) * remodeling index (absolute values) * total plaque volume (mm3) * calcified plaque volume (mm3) * non-calcified plaque volume (mm3) * low-attenuation plaque volume (mm3) * percentage of change in in-segment total plaque volume (%) * percentage of change in in-segment calcified plaque volume (%) * percentage of change in in-segment non-calcified plaque volume (%) * percentage of change in in-segment low-attenuation plaque volume (%) * percentage of change in in-segment remodeling index (%)
Time frame: 12-months
Clinical outcomes at 12-months follow-up
• the rate of target lesion failure (composite endpoint of cardiac death, target vessel-related myocardial infarction, or clinically-driven target lesion revascularization)
Time frame: 12-months
Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 21 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cardiology, Warsaw, Poland